B1 Receptor: Location, Function, and Medical Uses

The bradykinin B1 receptor (B1R) is a cell-surface receptor that sits quietly in most of your tissues under normal conditions, then ramps up dramatically when inflammation or tissue damage strikes. Unlike its close relative the B2 receptor, which is present in cells at all times, B1R is what researchers call “inducible,” meaning the body essentially builds new copies of it on demand in response to injury, infection, or oxidative stress. This unusual on-off quality has made it a compelling drug target for conditions from diabetic complications to chronic pain, though translating that promise into approved medicines has proven stubbornly difficult.

Where the B1 Receptor Normally Lives, and Where It Appears During Disease

In healthy tissue, B1R expression is low to undetectable. The receptor belongs to the gamma branch of class A G protein-coupled receptors (GPCRs), sharing only about 32 percent of its amino acid sequence with the B2 receptor, which is constitutively expressed throughout the body.¹ That low baseline is the receptor’s defining trait. It distinguishes B1R from most other receptors in the body, which tend to be present at relatively stable levels regardless of what’s happening around them.

Once inflammation kicks in, B1R shows up in a surprisingly wide range of cell types. Researchers have confirmed its expression in hypothalamic neurons when stimulated by angiotensin II, a hormone involved in blood pressure regulation.² It also appears on the endothelial cells lining blood vessels, on fat cells (adipocytes), on sensory neurons in the dorsal root ganglia (the clusters of nerve cell bodies near the spinal cord), on retinal cells during diabetic eye disease, and on airway cells during allergic and bacterial inflammation. The common thread is that B1R tends to emerge wherever the body is dealing with sustained damage or immune activation, not during the first few minutes of an injury but during the hours and days that follow.

How B1R Signals and Why It Does Not Shut Itself Off

Both B1R and B2R work through the same broad signaling cascade. They couple to Gq proteins, which activate an enzyme called phospholipase C, ultimately releasing calcium inside the cell.¹ That calcium surge is the trigger for many downstream effects, from blood vessel dilation to immune cell activation. Where the two receptors sharply diverge is in what happens after the signal fires.

The B2 receptor behaves the way most receptors do: once its ligand (bradykinin) binds, the receptor is quickly pulled inside the cell, a process called internalization. Within minutes, the B2 receptor loses surface expression, the ligand detaches, and the signal fades. The B1 receptor does almost none of this. Studies using cells engineered to express each receptor found that B1R showed virtually no ligand internalization or receptor loss from the cell surface after stimulation. Its ligand, des-Arg-kallidin, held on tightly even at body temperature, and signaling persisted without the usual fade.³ Even more strikingly, prolonged stimulation of B1R led to increased expression of the receptor itself, the opposite of the desensitization that most receptors undergo.

This persistent signaling behavior matters because it means once B1R appears in inflamed tissue, the inflammatory message doesn’t naturally taper off the way B2-mediated signaling does. The receptor keeps amplifying the signal for as long as the underlying inflammatory stimulus continues, and it can even outlast that stimulus. That self-reinforcing quality helps explain why B1R is so closely linked to chronic conditions rather than acute, short-lived responses.

The Role of B1R in Pain

Chronic inflammatory pain is one of the most studied consequences of B1R activation. When tissue is injured, B1R expression rises on nociceptive neurons, the nerve cells responsible for detecting harmful stimuli. Once present, the receptor sensitizes those neurons so that stimuli that would normally feel mild instead produce exaggerated pain, a phenomenon called hyperalgesia.⁴

Animal experiments have demonstrated this clearly. When formalin was injected into muscle to create an inflammatory insult, both B1 and B2 receptors were overexpressed, and the resulting mechanical hypersensitivity depended on both. Blocking B1R with antagonists prevented the hyperalgesia, and the pain pathway involved intracellular kinases known as p38, JNK, and PKC.⁵ Those kinases are well-known players in inflammatory signaling more broadly, which situates B1R squarely in the middle of the molecular machinery that maintains pain after the initial injury has occurred.

Human data, while thinner, point in the same direction. An analysis of sensory neurons from human dorsal root ganglia found that a donor’s history of chronic pain and older age were associated with higher B1R expression.⁶ That correlation doesn’t prove B1R caused the chronic pain, but it fits the broader picture from animal work and suggests the receptor’s relevance isn’t limited to laboratory models.

Vascular Permeability and Diabetic Complications

Beyond pain, B1R’s most thoroughly studied disease role involves blood vessel leakiness, especially in diabetes. Under normal conditions, the endothelial cells lining your blood vessels form a tight barrier that controls what passes between the bloodstream and surrounding tissue. B1R activation loosens that barrier. The receptor’s preferred ligand, des-Arg9-bradykinin, increases the permeability of endothelial cell layers to large molecules like albumin.⁷

In diabetic animals, the consequences of that leakiness are widespread. Rats with type 1 diabetes showed significantly increased vascular permeability in the aorta, kidneys, spleen, and heart. A selective B1R antagonist called R-954, given as a single dose, reduced plasma leakage by roughly half to completely in most of the affected tissues, with no effect on healthy animals.⁸ Similar results appeared in diabetic mice: a single intravenous dose of R-954 inhibited enhanced vascular permeability across most tissues tested.⁹

The eyes are especially vulnerable. Diabetic retinopathy, a leading cause of vision loss in adults with diabetes, involves breakdown of the blood-retinal barrier. In rat models, B1R mRNA levels in the retina rose significantly within two weeks of diabetes onset and remained elevated at six months. The receptor was present on both endothelial cells and glial cells in the retina, and its activation contributed to vascular inflammation and barrier breakdown.¹⁰ Blocking B1R reduced both skin and retinal vascular permeability in diabetic rats, raising the possibility that antagonists could be useful for diabetic neuropathy and retinopathy.¹¹

B1R in Fat Tissue, Insulin Sensitivity, and Obesity

A less intuitive role for B1R involves metabolism. Fat cells express the receptor, and its activity there appears to influence how the whole body handles insulin and glucose. Mice that lacked B1R entirely were leaner than normal mice. When researchers created a mouse strain where B1R was knocked out everywhere except in fat tissue, the animals stayed lean but lost the improved insulin sensitivity that fully B1R-knockout mice enjoyed. When those fat-only B1R mice were fed a high-fat diet, they gained as much weight as normal mice, suggesting B1R in adipocytes is enough to restore the predisposition to obesity.¹²

Pharmacological studies have reinforced this link. In mice fed a high-fat diet to model type 2 diabetes, a B1R antagonist called SSR240612 improved high blood sugar, high insulin levels, and insulin resistance. It also reduced markers of fat tissue inflammation. Interestingly, the B1R antagonist was more effective than the diabetes drug pioglitazone at reducing visceral fat and the hormone resistin, and combining the two treatments had an additive benefit on insulin sensitivity.¹³ These are animal findings, and the leap from mice to humans is always uncertain, but they point toward B1R as a player in the metabolic dysfunction that accompanies obesity.

B1R in the Brain, Lungs, and Heart

The receptor’s inflammatory reach extends to other organ systems. In the brain, angiotensin II stimulation of hypothalamic neurons upregulated B1R and simultaneously increased the expression of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α), boosted oxidative stress enzyme subunits, and activated the NF-κB signaling pathway. Blocking B1R reduced these effects.² Because neuroinflammation is implicated in conditions from Alzheimer’s disease to hypertension-related brain damage, B1R’s presence in hypothalamic neurons is more than a curiosity.

In the lungs, gram-negative bacteria produce endotoxin (lipopolysaccharide) that can trigger acute lung injury partly through B1R activation. Blocking B1R with R-954 inhibited eosinophil activation and proliferation in mouse models of asthma, suggesting a role in allergic airway disease as well.¹⁴

The heart is another frontier. Cardiac ischemia-reperfusion injury, the damage that occurs when blood flow returns to oxygen-starved heart tissue, involves endothelial barrier dysfunction. Researchers found that B1R activation during ischemia-reperfusion drove the expression of matrix metalloprotease 3 (MMP3), an enzyme that degrades connective tissue. A B1R antagonist abolished that MMP3 increase and improved endothelial barrier function, and MMP3 deletion itself protected cardiac function after ischemia-reperfusion.¹⁵ This is early-stage work, but it opens a potential path toward protecting the heart during events like heart attacks or cardiac surgery.

Connections to Cancer

B1R’s inducible, inflammation-linked nature has also drawn attention in oncology. Tumors are sites of chronic inflammation, and several cancer types show elevated B1R expression. In prostate cancer cells (the DU145 line), a B1R agonist stimulated both cell proliferation and migration at low concentrations, while a B2R agonist had no significant effect. Pre-treating the cells with a B1R antagonist blocked both the proliferation and migration.¹⁶ The fact that B1R but not B2R drove these tumor-promoting behaviors is consistent with B1R’s broader profile as a receptor tied to pathological states rather than normal physiology. It also makes B1R antagonists a candidate worth exploring in cancer therapy, though the research remains preclinical.

Why B1R Drug Candidates Keep Stalling

Given all of the above, you might expect B1R-targeting drugs to be well on their way to pharmacies. They are not. Multiple pharmaceutical companies have developed B1R antagonists and tested them in Phase I and Phase II clinical trials, and none has advanced to clinical use.¹⁷

Several factors may explain the gap between promising animal data and disappointing human trials. One issue is that B1R’s inducible nature makes it a moving target. The receptor is expressed at different levels depending on the type and stage of disease, so choosing the right patient population and timing for treatment is harder than it would be for a constitutively expressed receptor. Another challenge involves species differences. The genes for B1R and B2R have evolved at uneven rates across vertebrate lineages, leading to differing pharmacological properties between species.¹⁸ A compound that potently blocks B1R in rats or mice may not have the same affinity for the human version of the receptor. This kind of translational mismatch is common in drug development but is worth flagging here because so much of the B1R evidence comes from rodent models.

There is also the question of redundancy. Blocking B1R alone may not produce a dramatic clinical benefit if B2R and other inflammatory pathways can compensate for its loss. In many of the animal models, B1R and B2R work in tandem to produce inflammatory effects. Blocking one while the other keeps signaling may reduce symptoms without eliminating them, making it difficult to show a clear therapeutic win in a clinical trial where placebo effects, natural disease fluctuation, and other medications muddy the picture.

Researchers have also noted that the lack of B1R expression in healthy tissue, the very feature that makes it attractive as a drug target (less risk of disrupting normal functions), creates a practical problem: there is no easy biomarker or imaging approach to confirm that a patient’s disease is actively driven by B1R before enrolling them in a trial. Without that confirmation, trials may enroll patients whose disease isn’t B1R-dependent, diluting any treatment effect in the overall group.

B1R in Fat Cells as a Metabolic Drug Target

Among the various disease areas, metabolic disease may represent B1R’s most underappreciated therapeutic opportunity. The adipocyte-specific findings are especially notable because they suggest that B1R’s metabolic effects are not simply a downstream consequence of general inflammation but involve a direct role in how fat cells handle insulin signaling. The mouse study showing that restoring B1R expression only in fat tissue was enough to eliminate the insulin-sensitivity benefit of whole-body B1R deletion points to fat cells as the critical site of action.¹²

The additive benefit seen when combining a B1R antagonist with pioglitazone in high-fat-diet mice is another encouraging signal. Pioglitazone works primarily by activating a nuclear receptor in fat cells called PPARγ, while B1R antagonism appears to work through different pathways involving inflammation and possibly direct metabolic regulation. If those two mechanisms are genuinely independent, combination therapy might achieve more than either drug alone, a principle that has proven successful in other metabolic conditions like type 2 diabetes, where multi-drug regimens are now standard.¹³

How the B1 Receptor’s Self-Amplifying Behavior Shapes Disease

Perhaps the single most important concept for understanding why B1R matters in so many chronic conditions is the receptor’s refusal to desensitize. Most receptors in the body have built-in brakes. Once they are activated, they are pulled inside the cell, their signal fades, and the system resets. B1R lacks those brakes. Its ligand stays bound, the receptor remains on the cell surface, and prolonged stimulation actually increases the number of receptors present.³

This creates a positive feedback loop: inflammation induces B1R expression, B1R activation amplifies inflammatory signaling (via NF-κB and MAP kinase pathways), and that amplified inflammation induces even more B1R. In diseases where inflammation becomes self-sustaining, such as diabetic vascular disease, chronic pain, or the tumor microenvironment, this loop could be a critical mechanism that keeps the pathology going long after the original trigger has passed. Breaking that loop with an antagonist is the therapeutic logic behind every B1R drug candidate that has entered clinical testing. The challenge, as the trial failures suggest, is that breaking the loop in an animal model, where the disease is cleanly induced and the timing is controlled, is different from breaking it in a human patient with years of accumulated inflammatory damage and multiple interacting pathways.